CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 193 enrolled
Drug / intervention
Flulaval +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00902278
NCT00902278N/ACompleted

Immune Response Induced by Different Manufacturers of Influenza Vaccines

University of Massachusetts, Worcester·interventional·Posted May 15, 2009·Updated Nov 20, 2017

In Brief

A clinical study evaluating Flulaval, Fluvirin, and 3 other interventions for Immune Response. Completed, enrolled 193 participants across 1 site.

Detailed Summary

The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Response
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 15, 2009
Enrollment StartOct 1, 2008
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 17.1 years ago

Interventions

Flulavalbiological

one 0.5-mL dose via intramuscular injection

Fluvirinbiological

one 0.5-mL dose via intramuscular injection

Fluzonebiological

one 0.5-mL dose via intramuscular injection

Fluarixbiological

one 0.5-mL dose via intramuscular injection

Afluriabiological

one 0.5-mL dose via intramuscular injection